ProShare Advisors’s CorMedix CRMD Stock Holding History

ProShare Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$97K	Sell	14,288 -2,776	-16%	-$20.5K	﹤0.01%	1713
2025 Q4	$198K	Buy	17,064 +2,360	+16%	+$26.1K	﹤0.01%	1724
2025 Q3	$171K	Sell	14,704 -1,008	-6%	-$12.2K	﹤0.01%	1732
2025 Q2	$194K	Sell	15,712 -147	-0.9%	-$1.62K	﹤0.01%	1734
2025 Q1	$97.7K	Sell	15,859 -4,088	-20%	-$42.3K	﹤0.01%	1840
2024 Q4	$162K	Buy	19,947 +9,568	+92%	+$95.6K	﹤0.01%	1950
2024 Q3	$83.9K	Buy	+10,379	New	+$56.2K	﹤0.01%	1909

Other funds holding CRMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

ProShare Advisors's CRMD Position: Q1 2026 in Review

ProShare Advisors reduced its CorMedix (CRMD) stake by 16% in Q1 2026, selling an estimated $20.5K and leaving 14,288 shares worth $97K. The position accounts for ﹤0.01% of the portfolio, ranked #1713.

ProShare Advisors first reported a position in CRMD in Q3 2024 and has held it in 7 quarters since. The position peaked at $198K in Q4 2025. 187 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

ProShare Advisors held 14,288 shares of CorMedix worth $97K as of Q1 2026.
ProShare Advisors sold 2,776 CorMedix shares in Q1 2026, an estimated $20.5K.
CorMedix made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1713 holding.
ProShare Advisors first reported a position in CorMedix in Q3 2024 and has held it in 7 quarters since.
ProShare Advisors's CorMedix position peaked at $198K in Q4 2025.
187 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.